title: Recombinant Leishmania major lipophosphoglycan 3 activates human T-lymphocytes via TLR2-independent pathway.
abstract: Leishmaniasis is one of the most common infectious diseases transmitted by an obligate intracellular genus Leishmania. As there is no efficient vaccination strategy for leishmaniasis, new immunostimulatory components may enhance protective immune responses against this parasite. Lipophosphoglycan 3 (LPG3) is an essential protein required for LPG assembling. In this study, the ability of recombinant LPG3 (rLPG) and its fragments to activate isolated healthy human T-cells and cytokine secretion was evaluated in vitro. The results showed that rLPG3 and its N-terminal fragment (rNT-LPG3) enhanced expression of CD69 on the surface of T-cells and promoted differentiation of CD4(+) T-lymphocytes toward a T-helper 1 (T(H)1) phenotype, in part, through up-regulation of interferon (IFN)-γ expression in a TLR2-independent manner. These results indicated the protective effects of LPG3 (particularly NT-LPG3 fragment) as a potent immunostimulatory component of leishmania in vaccination against leishmaniasis. Further investigations in in vivo assays are clearly warranted.
authors.affiliation: a Drug Applied Research Center .|b Immunology Research Center , and.|c Department of Immunology , Tabriz University of Medical Sciences , Tabriz , Iran .
authors.forename: Maryam
authors.initials: M
authors.lastname: Hosseini
authors.affiliation: a Drug Applied Research Center .|b Immunology Research Center , and.|c Department of Immunology , Tabriz University of Medical Sciences , Tabriz , Iran .
authors.forename: Mostafa
authors.initials: M
authors.lastname: Haji Fatahaliha
authors.affiliation: b Immunology Research Center , and.|c Department of Immunology , Tabriz University of Medical Sciences , Tabriz , Iran .
authors.forename: Leili
authors.initials: L
authors.lastname: Aghebati-Maleki
authors.affiliation: b Immunology Research Center , and.|c Department of Immunology , Tabriz University of Medical Sciences , Tabriz , Iran .
authors.forename: Aliakbar
authors.initials: A
authors.lastname: Movassagh Pour
authors.affiliation: d Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran , Tehran , and.
authors.forename: Sima
authors.initials: S
authors.lastname: Rafati
authors.affiliation: b Immunology Research Center , and.|c Department of Immunology , Tabriz University of Medical Sciences , Tabriz , Iran .
authors.forename: Mehrnush
authors.initials: M
authors.lastname: Seifi-Najmi
authors.affiliation: e Department of Immunology , School of Public Health, Tehran University of Medical Sciences , Tehran , Iran.
authors.forename: Vahid
authors.initials: V
authors.lastname: Younesi
authors.affiliation: e Department of Immunology , School of Public Health, Tehran University of Medical Sciences , Tehran , Iran.
authors.forename: Farhad
authors.initials: F
authors.lastname: Jadidi-Niaragh
authors.affiliation: b Immunology Research Center , and.|c Department of Immunology , Tabriz University of Medical Sciences , Tabriz , Iran .
authors.forename: Mehdi
authors.initials: M
authors.lastname: Yousefi
mesh_terms: D005260:Female; D006028:Glycosphingolipids / Q000235:genetics / Q000276:immunology / Q000494:pharmacology; D006801:Humans; D018320:Leishmania major / Q000235:genetics / Q000276:immunology*; D054332:Leishmaniasis Vaccines / Q000235:genetics / Q000276:immunology / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects*; D008297:Male; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology / Q000494:pharmacology; D018417:Th1 Cells / Q000276:immunology*; D051195:Toll-Like Receptor 2 / Q000819:agonists / Q000276:immunology*
chemical_list: D006028:Glycosphingolipids; D054332:Leishmaniasis Vaccines; D011994:Recombinant Proteins; C495342:TLR2 protein, human; D051195:Toll-Like Receptor 2; C008290:lipophosphonoglycan
keywords: LPG3; T-cells; TLR2; leishmaniasis; vaccination